Not provided
Not provided
Not provided
Not provided
Slow enrollment and Covid-19
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hernia Reduction Prior to Scheduled TIF Completion using EsophyX ZR transoral device
Evaluation of the relative merits, safety and effectiveness of the EsophyX ZR transoral device in performing the standardized TIF 2.0 procedure preceded by laparoscopic Hiatal Hernia repair in PPI-prescribed patients with persistent "troublesome symptoms" per the Montreal consensus definition
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TIF using EsophyX ZR transoral device | Experimental | Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EsophyX ZR transoral device | Device | TIF |
|
| Measure | Description | Time Frame |
|---|---|---|
| pH Study | Number of Participants with Normalization of Esophageal Acid Exposure. Normalization in esophageal acid exposure is defined by ≤ 5.3% of total time pH < 4 in | 48 hour monitoring period |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With a Change in Troublesome Symptoms From Baseline | Per Montreal Consensus definition, troublesome symptoms are mild symptoms occurring two (2) or more days per week, or moderate/severe symptoms occurring more than 1 day per week | 6 months |
| Number of Participants With a Change in PPI Consumption From Baseline to 6 Months |
Not provided
Inclusion Criteria:
1. BMI > 35 2. Hiatal hernia ≤ 2 and > 4 cm 3. Esophagitis Los Angeles grade C or D 4. Esophageal ulcer 5. Esophageal stricture 6. Long-segment Barretts esophagus (Prague: C > 1, M > 3) 7. Esophageal motility disorder 8. Pregnancy or plans for pregnancy in the next 12 months (in females) 9. Immunosuppression 10. ASA > 2 11. Portal hypertension and/or varices 12. History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis 13. Active gastro-duodenal ulcer disease 14. Gastric outlet obstruction or stenosis 15. Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment 16. Coagulation disorders 17. Atypical symptoms including gas bloat and dysphagia. 18. Any other presenting condition that in the opinion of the investigator would not make participation in this study in the patient's best interest.
Post Enrollment Exclusion -
1. Inability to repair Hiatal hernia with at least 2cm of intra-abdominal esophagus length.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Murray, MD,FACS | Northern Nevada Medical Group | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Elkhart General Hospital | Elkhart | Indiana | 46514 | United States | ||
| Aspirus Iron River Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There were two sites that recruited patients. One was in Iron Mountain. Michigan and one in Sparks, Nevada. The procedures were done in hospitals. The recruitment was from August 18 2018 through February 2019. The study was closed by the sponsor due to slow enrollment.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | TIF Using EsophyX ZR Transoral Device | Prospective, investigator initiated, multicenter, non-randomized single arm, open label |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | TIF Using EsophyX ZR Transoral Device | Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device EsophyX ZR transoral device: TIF |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | pH Study | Number of Participants with Normalization of Esophageal Acid Exposure. Normalization in esophageal acid exposure is defined by ≤ 5.3% of total time pH < 4 in | Posted | Count of Participants | Participants | 48 hour monitoring period |
|
|
6 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | EsophyX ZR Transoral Device | Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device with Hiatal hernias ≤ 2 and > 4 cm. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bleeding, hematoma requiring intervention | Gastrointestinal disorders | Non-systematic Assessment | The patient admitted, 10 days post op, for bleeding. Required 2 units of blood. Possibly procedure related but not device related. Husband stated she carried heavy boxes. IRB notified . The issue resolved on 11/17/18. |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Cynthia Harris, Director of Clinical Trials | Daniel and Daniel Consulting, LLC | 775-392-2975 | cindy@clinregconsult.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Dec 19, 2017 | Nov 3, 2020 | Prot_SAP_ICF_000.pdf |
Not provided
Not provided
Not provided
Prospective, investigator initiated, multicenter, non-randomized single arm, open label.
Not provided
Not provided
Not provided
Not provided
from daily use to occasional use or none at all. |
| 6 months |
| Iron River |
| Michigan |
| 49935 |
| United States |
| Northern Nevada Medical Center | Sparks | Nevada | 89434 | United States |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
| Secondary | Number of Participants With a Change in Troublesome Symptoms From Baseline | Per Montreal Consensus definition, troublesome symptoms are mild symptoms occurring two (2) or more days per week, or moderate/severe symptoms occurring more than 1 day per week | The relatively small number of patients that were willing to come back for follow-up and assessment of outcome measure. | Posted | Count of Participants | Participants | 6 months |
|
|
|
| Secondary | Number of Participants With a Change in PPI Consumption From Baseline to 6 Months | from daily use to occasional use or none at all. | Posted | Count of Participants | Participants | 6 months |
|
|
|
| 0 |
| 14 |
| 1 |
| 14 |
| 0 |
| 14 |
|
Not provided
Not provided